OSI-774 |
CP-358774 |
R-1415 |
CP-35877401 |
ERLOTINIB |
TARCEVA |
CP-358,774 |
RG-1415 |
RO-508231 |
OSI 744 |
TARCEVA® |
NSC 718781 |
R 1415 |
[6,7-BIS-(2-METHOXY-ETHOXY)-QUINAZOLIN-4-YL]-(3-ETHYNYL-PHENYL)-AMINE |
drugbank:00530 |
chemidplus:183321-74-6 |
rxcui:337525 |
pubchem.compound:176870 |
chembl:CHEMBL553 |
Pharmaceutical Developer | Roche |
Source Reported Drug Name(s) | Erlotinib |
Drug Class | EGFR Inhibitor |
FDA Approval | Non-small cell lung cancer (with EGFR exon 19 deletions or exon 21 substitution (L858R) mutations), Pancreatic cancer |
Drug Class | Kinase Inhibitors |
Drug Class | antineoplastic agents, protein kinase inhibitors |
Year of Approval | 2004 |
FDA Approval | not approved |
Drug Class | Small Molecule |
Drug Indications | antineoplastic agent |
antagonist (inhibitory) |
inhibitor (inhibitory) |
combination therapy | MGCD265 + Erlotinib |
Approval Status | Phase III |
combination therapy | AUY922 + Erlotinib |
n/a |
combination therapy | ABT-263 + Alpelisib + Erlotinib + Trametinib |
Indication/Tumor Type | colorectal cancer |
Response Type | sensitive |
n/a |
Erlotinib | PubChem Drug Name |
176870 | PubChem Drug ID |
Tarceva | Drug Trade Name |
Drug Class | EGFR Inhibitor |
Source Reported Drug Name(s) | Erlotinib |
Pharmaceutical Developer | Roche |
OSI-774 | Development Name |
CP-258 | Development Name |
774 | Development Name |
Drug Class | Kinase Inhibitors |
FDA Approval | Non-small cell lung cancer (with EGFR exon 19 deletions or exon 21 substitution (L858R) mutations), Pancreatic cancer |
ERLOTINIB | Primary Drug Name |
Year of Approval | 2004 |
Drug Class | antineoplastic agents, protein kinase inhibitors |
Drug Indications | antineoplastic agent |
Drug Class | Small Molecule |
FDA Approval | not approved |
C2693 | NCI drug code |
C2693 | NCI drug code |
CHEMBL553 | ChEMBL Drug ID |
ERLOTINIB | Primary Drug Name |
ERLOTINIB | Drug Generic Name |
TARCEVA | Drug Trade Name |
D07POC | TTD Drug ID |